Anti-viral and anti-tumoral compounds
AssigneeYeda Research and Development Co. Ltd.
InventorsRotem SOREK, Auda BERNHEIM, Adl Jenny MILLMAN DAYAN
Life of this patent
Estimating the term…
Abstract
Disclosed herein are prokaryotic homologs of viperin (pVips), and nucleotide and nucleoside analogs produced from pVips. These nucleotide and nucleoside analogs stop nucleotide chain synthesis and provide host cells with resistance to viral infections by targeting actively replicating viral genome. Further, these nucleotide and nucleoside analogs decrease DNA replication in malignant cells. Further disclosed are methods of identifying pVips, and nucleotide and nucleoside analogs produced thereof.
Claims18
A method of treating a disease in a subject in need, said method comprising administering a nucleoside analog derived from a nucleotide analog produced by a prokaryotic homolog of viperin (pVip), or any combination of nucleoside analogs thereof, wherein said pVip has the amino acid sequence of one of SEQ ID NOs:409-789 or a homologue thereof comprising at least 80% homology to one of SEQ ID NOs:409-789, or wherein said pVip is encoded by a pVip gene comprising the sequence of one of SEQ ID Nos:3-408 or a homologue thereof comprising at least 80% identity to one of SEQ ID Nos:3-408:
- wherein said administration treats the disease.
A method of terminating polynucleotide chain synthesis in a cell, said method comprising introducing into said cell a nucleoside analog derived from a nucleotide analog produced by a prokaryotic homolog of viperin (pVip) or any combination of nucleoside analogs thereof, wherein said pVip has the amino acid sequence of one of SEQ ID NOs:409-789, or a homologue thereof comprising at least 80% homology to one of SEQ ID NOs:409-789, or wherein said pVip is encoded by a pVip gene comprising the sequence of one of SEQ ID Nos:3-408 or a homologue thereof comprising at least 80% identity to one of SEQ ID Nos:
- 3-408;
- wherein said introducing the nucleoside analog into the cell terminates polynucleotide chain synthesis in the cell.
A pharmaceutical composition comprising a pharmaceutical acceptable carrier and a nucleoside analog derived from a nucleotide analog produced by a pVip or any combination of nucleoside analogs thereof, wherein said pVip has the amino acid sequence of one of SEQ ID NOs:409-789 or a homologue thereof comprising at least 80% homology to one of SEQ ID NOs:409-789, or wherein said pVip is encoded by a pVip gene comprising the sequence of one of SEQ ID Nos:
- 3-408 or a homologue thereof comprising at least 80% identity to one of SEQ ID Nos:3-408.
A nucleic acid construct comprising (i) a polynucleotide encoding a prokaryotic homologs of viperin (pVip), wherein said pVip has the amino acid sequence of one of SEQ ID NOs:409-789 or a homologue thereof comprising at least 80% homology to one of SEQ ID NOs:409-789, or wherein said pVip is encoded by a pVip gene comprising the sequence of one of SEQ ID Nos:3-408 or a homologue thereof comprising at least 80% identity to one of SEQ ID Nos:3-408;
- and (ii) a non-naturally occurring regulatory element operably linked to said polynucleotide.
Dependencies are inferred from the claim text.